Constarium
← Search

Data · dataset · 2026

Real-world evaluation of 2023–2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial

Listed in ZivaHub and Deakin Research Online — shown once because both records carry DOI 10.6084/m9.figshare.34030331.v1

<p>The objective of this analysis was to assess reactogenicity profile differences between a protein- and mRNA-based COVID-19 vaccine in participants who had previously received ≥2 doses of an mRNA-based vaccine in a real-world, double-blinded, randomized, controlled trial.

Description

In the BEEHIVE/NCT06065176 trial (ClinicalTrials.gov: NCT06065176), participants randomized 1:1 received one dose of the Novavax (NVX) or Pfizer–BioNTech (PFZ) COVID-19 vaccine 2023–2024 formulation (XBB.1.5); a comparator group did not receive a dose.

Electronic surveys collected solicited systemic (fatigue, fever, headache, joint pain, malaise/feeling sick, muscle pain, and nausea/vomiting) and local (injection-site pain, tenderness, and swelling) events on days 1, 2, and 6 after study vaccination. Significantly lower proportions of participants in the NVX (n = 448) vs. PFZ (n = 453) group reported a systemic (62.1% vs. 75.7%; risk difference −13.7%, 95% CI: −19.6% to −7.7%) or local (81.0% vs. 92.7%; risk difference −11.7%, 95% CI: −16.0% to −7.3%) event in the day-1 survey (both Cochran–Mantel–Haenszel <i>P</i> < .0001).

Read the rest (2 more)

Most events were mild. Reactogenicity rates decreased throughout the week; >80% and >94% of participants in either group reported no systemic or local reactogenicity, respectively, in the day-6 survey. Mean number of events/person were significantly lower for the NVX vs. PFZ group in the day-1 (systemic and local) and day-2 (local) surveys (each <i>P</i> < .0001).

There were significant differences in reactogenicity profiles for the 2023–2024 formulations of the NVX and PFZ COVID-19 vaccines, with NVX consistently associated with lower reactogenicity rates than PFZ.</p>

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 2 source records, 14 field assertions
SourceKeyLast seenRaw
ZivaHuboai:figshare.com:article/340303319 d agoJSON v1
Deakin Research Onlineoai:figshare.com:article/340303319 d agoJSON v1
FieldAssertionExtractorEvidence
concepts[disease].local:disease:cancermapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Cancer']
concepts[disease].local:disease:cancermapping · dro deakin edu auvocabulary-mapper@1.0.0keywords['Cancer']
concepts[field].anzsrc:group:3204mapping · zivahub uct ac zavocabulary-mapper@1.0.0keywords['Immunology']
concepts[field].anzsrc:group:3204mapping · dro deakin edu auvocabulary-mapper@1.0.0keywords['Immunology']
concepts[field].local:field:earth-environmentalmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:earth-environmentalmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:medicine-healthmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:medicine-healthmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:psychology-behavioralmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:psychology-behavioralmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
descriptionsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/description
license_textsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
publication_datesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
titlesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/title